Q-omics provides the consensus-scored CDH19 profile across patient tissues and cancer cell-line models. CDH19 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CDH19 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, CDH19 protein abundance shows 21,842 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LGG, COAD, and LSCC as cancer lineages where CDH19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDH19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDH19 survival associations across molecular data types. CDH19 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDH19 RNA expression–survival associations across cancer types. High CDH19 expression shows unfavorable associations in LGG, BLCA, KIRC, UCEC and UCS, but favorable associations in CESC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CDH19 RNA expression.
This table summarizes CDH19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CDH19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDH19 shows lower tumor expression in COAD, BLCA, LUAD, THCA, KIRC and LUSC. The COAD box plot shows higher CDH19 RNA expression in normal versus tumor tissue (log2 FC = −1.831, t-test p < 0.001).
This table shows molecular features associated with CDH19 in patient tissues and cancer cell lines. In patient samples, CDH19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDH19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
